OPTINOSE INC (OPTN) Stock Price & Overview
NASDAQ:OPTN • US68404V2097
The current stock price of OPTN is 9.6 USD. Today OPTN is down by -1.13%. In the past month the price increased by 4.69%. In the past year, price decreased by -42.34%.
OPTN Key Statistics
- Market Cap
- 97.248M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.73
- Dividend Yield
- N/A
OPTN Stock Performance
OPTN Stock Chart
OPTN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to OPTN. When comparing the yearly performance of all stocks, OPTN is one of the better performing stocks in the market, outperforming 82.3% of all stocks.
OPTN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OPTN. OPTN has a bad profitability rating. Also its financial health evaluation is rather negative.
OPTN Earnings
On May 14, 2025 OPTN reported an EPS of -1.92 and a revenue of 18.51M. The company missed EPS expectations (-154.37% surprise) and beat revenue expectations (2.53% surprise).
OPTN Forecast & Estimates
10 analysts have analysed OPTN and the average price target is 9.18 USD. This implies a price decrease of -4.37% is expected in the next year compared to the current price of 9.6.
For the next year, analysts expect an EPS growth of 1.39% and a revenue growth 27.03% for OPTN
OPTN Groups
Sector & Classification
OPTN Financial Highlights
Over the last trailing twelve months OPTN reported a non-GAAP Earnings per Share(EPS) of -2.73. The EPS decreased by -40% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.65% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OPTN Ownership
OPTN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.65 | 944.634B | ||
| JNJ | JOHNSON & JOHNSON | 20.92 | 587.317B | ||
| MRK | MERCK & CO. INC. | 22.63 | 289.492B | ||
| PFE | PFIZER INC | 9.1 | 154.439B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.49 | 122.453B | ||
| ZTS | ZOETIS INC | 17.02 | 50.862B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.9 | 26.518B | ||
| VTRS | VIATRIS INC | 5.61 | 16.212B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.5 | 11.768B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.508B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.528B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.81B | ||
| LGND | LIGAND PHARMACEUTICALS | 25 | 4.233B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OPTN
Company Profile
OptiNose, Inc. operates as a pharmaceutical company. The company is headquartered in Yardley, Pennsylvania and currently employs 127 full-time employees. The company went IPO on 2017-10-13. The firm's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. The company has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.
Company Info
IPO: 2017-10-13
OPTINOSE INC
777 Township Line Road, Suite 300
Yardley PENNSYLVANIA 19067 US
CEO: Peter K. Miller
Employees: 128
Phone: 12673643500
OPTINOSE INC / OPTN FAQ
What does OPTN do?
OptiNose, Inc. operates as a pharmaceutical company. The company is headquartered in Yardley, Pennsylvania and currently employs 127 full-time employees. The company went IPO on 2017-10-13. The firm's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. The company has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.
What is the current price of OPTN stock?
The current stock price of OPTN is 9.6 USD. The price decreased by -1.13% in the last trading session.
Does OPTINOSE INC pay dividends?
OPTN does not pay a dividend.
What is the ChartMill rating of OPTINOSE INC stock?
OPTN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is OPTINOSE INC (OPTN) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on OPTN.
How many employees does OPTINOSE INC have?
OPTINOSE INC (OPTN) currently has 128 employees.